Allo BMT in Advanced Leukemia or High Grade Lymphoma

Not Applicable

Completed

• Conditions: Lymphoma, Non-Hodgkin; Leukemia; Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin

• Registration Number: NCT00186290
• Lead Sponsor: Stanford University

Brief Summary

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Detailed Description

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Study Timeline

• Study Start: 1989-12
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2009-10
• Study Completion: 2009-10
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-07
• Last Update Posted: 2010-10-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 145

Inclusion Criteria

HLA identical donor

• adequate organ function
• other life threatening disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
overall survival	october 2009
disease free survival	October 2009

Secondary Outcome Measures

Name	Time	Method
early and late toxicities of the treatment regimen	October 2009

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States